Trial · NCT06529406
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
NCT06529406, Phase 4, Recruiting, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod. Trials, record NCT06529406. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06529406
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
- NCT number
- NCT06529406
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ozanimod
- First posted
- 2024-07-31
- Last updated
- 2025-09-18
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | New T2 lesions count | 36 months | Number of new T2 lesions on MRI scans. |
| Primary | Serious infections | 36 months | Infections requiring hospitalization, intravenous antibiotic use, or prolonged antibiotic use for treatment of an infection for at least 30 days. |
| Secondary | Relapses | 36 months | Protocol and/or suspected relapses |
| Secondary | IgG and IgM levels | 36 months | IgG and IgM levels |
| Secondary | Infections | 36 months | All infections including opportunistic infections. |
| Secondary | No Evidence of Disease Activity (NEDA-3) | 36 months | Not meeting any of the following criteria: 1. Evidence of Relapse activity - collected every 3 months via phone calls/clinic visits. 2. MRI disease activity - presence of new T2 lesions from MRI scans conducted at any timepoint. 3. 6 months Confirmed Disability progression (CDP6): measured by the EDSS assessed at baseline and every 6 months. CDP6 is defined as an increase in Expanded Disability Status Scale (EDSS) score of ≥1.5 if baseline EDSS was 0; or ≥1.0 points if baseline EDSS was ≥0.5-≤5.5; or by ≥0.5 points if baseline EDSS ≥6, sustained over two consecutive visits. |
| Secondary | Neurofilament light (NfL) and Glial Fibrillary Acid Protein (GFAP) | 36 months | Neurofilament light (NfL) and Glial Fibrillary Acid Protein (GFAP) |
| Secondary | Brain parenchymal and thalamic volume loss | 36 months | Brain parenchymal and thalamic volume loss |
| Secondary | Adverse Events | 36 months | Adverse Events |
| Other | Symbol Digital Modalities Test | 36 months | A 4 points or 10% change in cognition |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06529406
GET https://conductscience.org/api/trials/v1/NCT06529406/registered